170 related articles for article (PubMed ID: 18378708)
21. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
23. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Tsuji BT; Rybak MJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
[TBL] [Abstract][Full Text] [Related]
24. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.
Pogliano J; Pogliano N; Silverman JA
J Bacteriol; 2012 Sep; 194(17):4494-504. PubMed ID: 22661688
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.
Diederen BM; van Duijn I; Willemse P; Kluytmans JA
Antimicrob Agents Chemother; 2006 Sep; 50(9):3189-91. PubMed ID: 16940127
[TBL] [Abstract][Full Text] [Related]
26. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
Cui L; Tominaga E; Neoh HM; Hiramatsu K
Antimicrob Agents Chemother; 2006 Mar; 50(3):1079-82. PubMed ID: 16495273
[TBL] [Abstract][Full Text] [Related]
27. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
28. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
[TBL] [Abstract][Full Text] [Related]
29. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Cha R; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
[TBL] [Abstract][Full Text] [Related]
30. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin.
Sader HS; Jones RN
Clin Infect Dis; 2006 Sep; 43(6):798-9; author reply 799-800. PubMed ID: 16912964
[No Abstract] [Full Text] [Related]
31. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
Credito K; Lin G; Appelbaum PC
Antimicrob Agents Chemother; 2007 Apr; 51(4):1504-7. PubMed ID: 17220402
[TBL] [Abstract][Full Text] [Related]
32. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
Hobbs JK; Miller K; O'Neill AJ; Chopra I
J Antimicrob Chemother; 2008 Nov; 62(5):1003-8. PubMed ID: 18669516
[TBL] [Abstract][Full Text] [Related]
33. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of daptomycin against multidrug-resistant Staphylococcus aureus and S. aureus with known virulence factors, including community-acquired methicillin-resistant isolates.
Anastasiou DM; Morgan M; Ruane PJ; Steenbergen JN; Katz BD; Alder JD; Thorne GM
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):339-42. PubMed ID: 18304772
[TBL] [Abstract][Full Text] [Related]
35. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.
Velazquez A; DeRyke CA; Goering R; Hoover V; Wallace MR
Clin Microbiol Infect; 2013 Dec; 19(12):1169-72. PubMed ID: 23480569
[TBL] [Abstract][Full Text] [Related]
36. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
[TBL] [Abstract][Full Text] [Related]
37. A novel mutation in the vraS gene of Staphylococcus aureus contributes to reduce susceptibility against daptomycin.
Su J; Iehara M; Yasukawa J; Matsumoto Y; Hamamoto H; Sekimizu K
J Antibiot (Tokyo); 2015 Oct; 68(10):646-8. PubMed ID: 25899124
[No Abstract] [Full Text] [Related]
38. Increasing Trend of Heterogeneous Vancomycin Intermediate Staphylococcus aureus in a Tertiary Care Center of Northern India.
Singh A; Prasad KN; Misra R; Rahman M; Singh SK; Rai RP; Tripathi A; Srivastava JK
Microb Drug Resist; 2015 Oct; 21(5):545-50. PubMed ID: 26430942
[TBL] [Abstract][Full Text] [Related]
39. Activity of daptomycin against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae.
Sorlozano A; Gutiérrez J; Roman J; Liebana J; Piedrola G
Microb Drug Resist; 2009 Jun; 15(2):125-7. PubMed ID: 19432525
[TBL] [Abstract][Full Text] [Related]
40. An Acyl-Linked Dimer of Daptomycin Is Strongly Inhibited by the Bacterial Cell Wall.
Taylor RM; Scott B; Taylor S; Palmer M
ACS Infect Dis; 2017 Jul; 3(7):462-466. PubMed ID: 28350438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
